SuperworthPTC Therapeutics free cash flow PTCT
Cash from operations less capital spending, by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$39.7M
- Latest quarter, Q2 FY26
- $126.9M
- Fiscal year 2025
- $702.4M
PTC Therapeutics' free cash flow was −$39.7M over the twelve months to Jun 30, 2026, down 106% on a year earlier.
In its latest quarter, Q2 FY26, it was $126.9M.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $702.4M | n/a |
| FY2024 | −$114.2M | n/a |
| FY2023 | −$186.9M | n/a |
| FY2022 | −$388.7M | n/a |
| FY2021 | −$279.5M | n/a |
| FY2020 | −$211.9M | n/a |
| FY2019 | −$112.4M | n/a |
| FY2018 | −$34.7M | n/a |
| FY2017 | −$13.2M | n/a |
| FY2016 | −$105.3M | n/a |
| FY2015 | −$127.1M | n/a |
| FY2014 | −$61.9M | n/a |
| FY2013 | −$47.8M | n/a |
| FY2012 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $126.9M | n/a | −$39.7M | |
| Q1 FY26 | −$60.2M | −107% | −$226.2M | |
| Q4 FY25 | −$36.6M | n/a | $702.4M | |
| Q3 FY25 | −$69.7M | n/a | $705.3M | |
| Q2 FY25 | −$59.6M | n/a | $697.5M | |
| Q1 FY25 | $868.4M | +1320% | $693M | |
| Q4 FY24 | −$33.8M | n/a | −$114.2M | |
| Q3 FY24 | −$77.5M | n/a | −$186.3M | |
| Q2 FY24 | −$64.1M | n/a | −$129.6M | |
| Q1 FY24 | $61.2M | n/a | −$85.9M | |
| Q4 FY23 | −$105.9M | n/a | −$186.9M | |
| Q3 FY23 | −$20.9M | n/a | −$255.6M |
Against its peers
Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| PTCTPTC Therapeutics | −0.8% |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| LGNDLigand Pharmaceuticals | 2.2% |
| INDVIndivior Pharmaceuticals | −2.7% |
| AMRXAmneal Pharmaceuticals | 2.0% |
| ARQTArcutis Biotherapeutics | 1.0% |
| LQDALiquidia | 3.9% |
| OGNOrganon | 15.7% |
| ALKSAlkermes plc. | 3.0% |
| TGTXTG Therapeutics | 0.2% |
| PTGXProtagonist Therapeutics | 1.5% |
| Peer median | 2.1% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on PTC Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.